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Discussion
• Based on the studies discussed, DPP-IV inhibitors have been 
shown to improve glycemic control and, based on the small trials, 
appear to have great potential to provide beneficial cardiovascular 
effects due to their positive impact on reducing inflammatory 
markers. 
• GLP-1 agonists also appear to have similar benefits as DPP-IV 
inhibitors with the added benefit of weight loss. In addition, 
patients with type 2 diabetes frequently have coagulation 
abnormalities leading to a prothrombotic state.  Thus the 
reduction in fibrinogen, C-reactive protein and plasminogen 
activator inhibitor observed during the review of literature 
supports the potential of DPP-IV inhibitors and GLP-1 agonists 
having an antithrombotic effect. 
• A decrease in HgbA1c, inflammatory markers (e.g. CRP, TNF-α), 
Free Fatty Acids and Triglycerides were common themes 
presented during the review of literature looking specifically at 
the role of DPP-IV inhibitors and their impact on increasing 
GLP-1.
• DPP-IV inhibitors have been shown to be well tolerated, weight 
neutral and less expensive.  They do, however have less of an 
impact on A1c as compared to the GLP-1 analogues. 
• A common theme found with GLP-1 analogues, as seen with 
DPP-IV inhibitors, is the reduction in the inflammatory markers 
independent of changes in weight. Oxidative stress as measured 
by PGF2α, was found to also decrease with the addition of a 
GLP-1 analogue.
• Hypoglycemic events were essentially non-existent with DPP-IV 
inhibitors and GLP-1 analogues.
There is a strong established relationship between diabetes and 
cardiovascular disease. Much of the latest research studies have 
identified a link between the inflammatory processes and the 
pathogenesis of both cardiovascular disease and diabetes. Specific 
inflammatory markers include: Interleukins 1,6,18; C-reactive 
protein, Fibrinogen, Tumor Necrosis Factor-α , PAI-I and cell 
adhesion molecules. As a result, there has been an emphasis on 
identifying therapeutic approaches that would improve both 
markers of inflammation and glucose control. The endocrine 
hormones known as incretins, glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP), are produced 
in the gastrointestinal tract following ingestion of a meal. In 
individuals with type 2 diabetes, endothelial dysfunction associated 
with premature atherosclerosis has been well documented. The 
purpose of this paper is to determine whether increasing levels of 
GLP-1 reduce markers of inflammation while improving both 
glucose control and cardiovascular risk factors. The review of 
literature explored the impact of increasing GLP-1, either though 
DPP-IV inhibitors or GLP-1 analogues, on various inflammatory 
markers in patients with type 2 diabetes. The studies reviewed 
provided ample support for the use of DPP-IV inhibitors to improve 
both glycemic control and cardiovascular risk factors. GLP-1 
analogues also appear to have a similar impact, but with the added 
benefit of weight loss. In addition, patients with type 2 diabetes 
frequently have coagulation abnormalities leading to a 
prothrombotic state. Thus the reduction in fibrinogen, C-reactive 
protein and plasminogen activator inhibitor observed during the 
review of literature supports the potential for DPP-IV inhibitors and 
GLP-1 agonists to exhibits an antithrombotic effect.  These findings 
are of clinical significance as these treatments may potentially slow 
the progression of premature cardiovascular disease as well as 
reduce thrombotic events in patients with type 2 diabetes. 
• An article search of the following electronic medical databases 
was conducted; PubMed, The Cochran Library, DynaMed and 
MEDLINE. A combination of keywords and subject headings 
were used, with search terms including: type 2 diabetes, DPP-
IV inhibitors, GLP-1 agonist, incretins, inflammation, 
cardiovascular disease. 
• Full articles were retrieved for further review if the information 
given suggested that the study: included patients with type two 
diabetes mellitus, measured pre and post markers of 
inflammation, cardiovascular risk factors or changes in glucose 
following either a DPP-IV inhibitor or a GLP-1 agonist active 
intervention.
• Tremblay et al. 2014 conducted a double blinded, cross over 
study using Sitagliptin (Januvia) or placebo.  Thirty men and six 
postmenopausal women, (who were not receiving HRT), with 
type 2 diabetes participated in the study. Mean age and BMI, 
58.1 and 30.7, respectively. The treatment with 100mg of 
Sitagliptin significantly reduced the levels of CRP, IL-6 and IL-
18 by -44.9% (P = 0.006), -24.7% (P = 0.04) and -7.3% (P = 
0.004), respectively. Additional findings included a significant 
inverse correlation between changes in GLP-1 and changes in 
CRP levels (r = 0.41, P = 0.01) with Sitagliptin therapy vs 
placebo. In the fasting state, Sitagliptin led to significant 
reductions in plasma cholesterol (-5.1%, P = 0.001). apoB (-
4.7%, P = 0.003), and LDL-C (-5.2%, P = 0.003) without 
affecting plasma levels of triglycerides, free fatty acids and 
HDL-C when compared to placebo. 
• In a 12 week single center, randomized placebo controlled 
double blinded prospective study, Makdissi et al. 2012, enrolled 
22 obese subjects with type 2 diabetes with hemoglobin A1c 
between 7.5% and 9%.  None of the subjects had any 
micro/macrovascular complications of diabetes. Subjects were 
randomized to receive either Sitagliptin 100mg (N = 12; 6 male 
and 6 female) or placebo (N = 10). Results showed fasting 
GLP-1 concentrations increased 63% ± 20% (from 9.1 ± 2.8 to 
15.8 ± 4.0) at 12 weeks.  A significant reduction in plasma 
concentrations of CRP and IL-6 by 24 ± 7 and 24 ± 8%, 
respectively (P <0.05) in the Sitagliptin treated group. HgbA1c 
fell significantly from 7.6 ± 0.1 to 6.9 ± 0.3% (P < 0.01), serum 
triglycerides decreased from 209 ± 20 to 159±19mg/dl.  There 
was no significant changes in BMI, blood pressure or 
cholesterol concentrations in either the treatment or placebo 
groups. 
• Pettigrew, et al. assessed the effect of Liraglutide on biomarkers 
for cardiovascular risk in patients with type 2 diabetes. The 
researchers randomized 165 patients with type 2 diabetes to 
either a placebo or 0.65mg. 1.25mg or 1.9mg of Liraglutide for 
14 weeks. Pre and post measurements of hsCRP, IL-6, TNF-α 
and plasminogen activator inhibitor (PAI-1) and B-type 
natriuretic peptide (BNP) were measured. Results showed a 
significant decrease between baseline levels of PAI-1 and BNP 
levels following higher dose treatment (1.25mg and 1.90mg) of 
Liraglutide,( -29%; P = 0.018 and -25%; P = 0.045, 
respectively. There was a non-significant, but dose dependent 
reduction in hsCRP; (0.65mg = -3%; P = 0.85; 1.25mg = -12%; 
P=0.46; 1.90mg = -20%; P = 0.22).
• The findings of this research project are applicable to several 
areas of clinical practice. The literature supports the anti-
inflammatory effect of both DPP-IV inhibitors and GLP-1. While 
these pharmacologic therapies have been on the market for over a 
decade, there utilization is not optimized. 
• Given the minimal risk of hypoglycemia associated side effects 
with both DPP-IV inhibitors and GLP-1 analogs, as well as their 
impact on HgbA1c reduction, it seems most appropriate for there 
to be a shift in the prescribing habits of clinicians as they work 
with patients to help achieve improved glycemic control.
• Both of these classes of therapy have been shown to reduce 
markers of inflammation, which shows promise in reducing the 
progression of cardiovascular disease and possibly thrombotic 
events.
• Clinicians will be assisting patients with not only managing 
glucose with anti-diabetes medications, but also cardiovascular 
risk factors.  Lifestyle modification, albeit challenging for 
patients to embrace and sustain, is part of the practice guidelines 
regardless of where the patient falls in the algorithm and should 
remain part of the treatment plan. 
• Clinicians should be working with patients to enhance 
management of all comorbidities associated with diabetes, 
especially cardiovascular. It seems reasonable to select diabetes 
medications that will target both chronic diseases. There are oral 
medications on the market that have combined DPP-IV inhibitors 
with metformin. 
• Clinicians need to be current and relevant in both medical and 
pharmacologic knowledge, which impacts their prescribing habits 
and quality of patient care. 
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The relationship between diabetes and cardiovascular disease has 
been the focus of many empirical investigations.  Across time, 
researchers have explored a link between inflammatory processes 
and the pathogenesis of both diabetes and cardiovascular disease.   
Consequently, there has been an emphasis on identifying 
therapeutic approaches that would improve both markers of 
inflammation and glucose control; thereby slowing the progression 
of premature cardiovascular disease in patients with type 2 
diabetes.  The purpose of this review is to examine the role of 
increased levels of GLP-1 in reducing markers of inflammation.
Given the known relationship between diabetes, premature 
cardiovascular disease and the inflammatory involvement; it is 
important to explore inflammatory markers and therapies that may 
reduce their negative impact on endothelial function. The author expresses sincere appreciation to both Terri Wold and 
Dr. Sue Kuntz who served as faculty advisors and mentors for this 
project. It has been a pleasure working with both of you as well as 
the rest of the faculty and staff within the Department of Physician 
Assistant Studies at the University of North Dakota School of 
Medicine and Health Sciences.
Research Question
In patients with type 2 diabetes, does increasing GLP reduce 
markers of inflammation, while improving both glucose control 
and cardiovascular risk factors.
Figure 1. Adapted from “Selective targeting of glucagon-
like peptide-1 signaling as a novel therapeutic approach for 
cardiovascular disease in diabetes”, by M. Tate, A. Chong, 
E. Robinson, B. Green and D. Grieve, 2014, British 
Journal of Pharmacology, e172. Copyright 2014 by the 
British Pharmacological Society.
